Vera Yu. Kabargina
Research Subjects
Vera Yu. Kabargina has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Irina I. Amiantova
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова», Москва, Российская Федерация
5 shared publications - Lyubov N. Nesterenko
I. Mechnikov Research Institute of Vaccines and Sera
5 shared publications - Vera V. Dotsenko
Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова», Москва, Российская Федерация
5 shared publications - Galina Ivanovna Alatortseva
I. Mechnikov Research Institute of Vaccines and Sera
4 shared publications - L. N. Pritvorova
Federal State Budgetary Scientific Institution «I. Mechnikov Research Institute for Vaccines and Sera», Moscow, Russian Federation
4 shared publications - Vitaliy Vasilievich Zverev
I.I. Mechnikov Institute of Vaccines and Sera, 105064 Moscow, Russia
4 shared publications
Latest Publications
- 7 March 2026
- Published by Establishment "RSPJHCK" in Scientific and Practical Journal Healthcare of Kyrgyzstan
- No. 1,p. 36-47
Разработка иммуноферментной тест-системы для количественного определения IgG-антител к вирусу гепатита Е в сыворотке крови человека и оценка ее диагностической эффективности
Введение. Для выявления антител к вирусу гепатита Е (ВГЕ) наиболее предпочтительным является метод иммуноферментного анализа (ИФА) с количественной оценкой результатов. Данный подход, основанный на строгих критериях, обеспечивает прецизионное определение концентрации антител, что позволяет проводить достоверную диагностику и эпидемиологический мониторинг. Цель исследования. Разработка тест-системы для определения концентрации IgG-антител к ВГЕ в сыворотке крови человека методом непрямого ИФА и оценка ее диагностической эффективности. Материалы и методы. Наборы реагентов «ДС-ИФА-АНТИ-HEV-G» (ООО «НПО Диагностические системы», Россия) и recomWeel HEV IgG (Euroimmun, Германия). Международный стандартный образец ВОЗ Anti-Hepatitis E Serum, Human code: 95/584 (NIBSC, Англия). Иммунореагенты, полученные в ФГБНУ НИИВС им. И.И. Мечникова: рекомбинантный антиген ORF2/3-ВГЕ1/3, моноклональные антитела к IgG человека («Сорбент», Россия), конъюгированные с пероксидазой хрена, специфические поликлональные антитела кролика к белку ORF2/3-ВГЕ1/3, конъюгированные с IgG человека. Сыворотки крови здоровых людей и лиц, инфицированных вирусами гепатитов А, В, С, Е, ВИЧ и герпесвирусами. Результаты и обсуждение. Разработана иммуноферментная тест-система «Скрин-ВГЕ-IgG» для определения концентрации IgG к вирусу гепатита Е (МЕ/мл) в сыворотке крови человека в непрямом формате. Синтезирован и стандартизирован по международному ВОЗ-стандарту Anti-Hepatitis E Serum, Human, NIBSC code: 95/584, искусственный калибратор для определения концентрации АТ-ВГЕ. Определены основные функциональные характеристики «Скрин-ВГЕ-IgG» в соответст- вии с требованиями ГОСТ 51352-2013. Тест-система апробирована на образцах сывороток крови больных гепатитом Е (n = 75) и условно здоровых лиц (n = 320). По данным ROC-анализа, диагностическая чувствительность тест-системы составляет 98,7 %, диагностическая спе- цифичность — 99,9 %. Показано отсутствие перекрестной реактивности «Скрин-ВГЕ-IgG» на образцах с серологическими маркерами других вирусных гепатитов и патологии печени иной этиологии (n = 83). Сравнительные испытания тест-системы «Скрин-ВГЕ-IgG» и ее коммерческого аналога – набора реагентов recomWeel HEV IgG, — показали более высокую диагностическую чувствительность разработан- ной тест-системы. Заключение. Разработанная тест-система обладает высокими показателями диагностической эффективности и может быть рекомендована к применению в клинической практике для определения концентрации IgG-антител к ВГЕ. Introduction. To detect antibodies to the hepatitis E virus (HEV), the enzyme-linked immunosorbent assay (ELISA) is the preferred method with a quantitative assessment of results. This method, based on strict criteria, al- lows for the precise determination of the quantity of antibodies, enabling reliable diagnosis and epidemiological monitoring. The aim. To develop a test system for measuring the concentration of IgG antibodies against HEV in human serum using indirect ELISA, and to evaluate its diagnostic accuracy. Materials and methods. Reagents kits «DS-ELISA-ANTI-HEV-G» (Diagnostic Systems, Russia) and «recomWeel HEV IgG» (Euroimmun, Germany) were used, as well as WHO International Standard Samples of Anti- Hepatitis E Serum (NIBSC, England) and immunoreagents from the «I.I. Mechnikov Research Institute of Vaccines and Sera»: recombinant antigen ORF2/3-HEV1/3, monoclonal antibodies to human IgG conjugated with horseradish peroxidase (Sorbent, Russia), and specific polyclonal rabbit antibodies for the protein ORF2/3-HEVI/3 conjugated with human IgG. Blood serum samples from healthy individuals and those infected with hepatitis A, B, C, E, HIV and herpes viruses. Results and discussion. It has been developed of enzyme immunoassay kit reagents called «Screen-HEV-IgG» to determine the concentration of hepatitis E virus IgG (AT-HEV) in human blood serum. The kit uses an indirect ELISA method to measure the concentration of AT-HEV in IU/ml. An artificial calibrator has been synthesized and standardized based on the World Health Organization's...
- 7 March 2026
- Published by Establishment "RSPJHCK" in Scientific and Practical Journal Healthcare of Kyrgyzstan
- No. 1,p. 36-47
Разработка иммуноферментной тест-системы для количественного определения IgG-антител к вирусу гепатита Е в сыворотке крови человека и оценка ее диагностической эффективности
Введение. Для выявления антител к вирусу гепатита Е (ВГЕ) наиболее предпочтительным является метод иммуноферментного анализа (ИФА) с количественной оценкой результатов. Данный подход, основанный на строгих критериях, обеспечивает прецизионное определение концентрации антител, что позволяет проводить достоверную диагностику и эпидемиологический мониторинг. Цель исследования. Разработка тест-системы для определения концентрации IgG-антител к ВГЕ в сыворотке крови человека методом непрямого ИФА и оценка ее диагностической эффективности. Материалы и методы. Наборы реагентов «ДС-ИФА-АНТИ-HEV-G» (ООО «НПО Диагностические системы», Россия) и recomWeel HEV IgG (Euroimmun, Германия). Международный стандартный образец ВОЗ Anti-Hepatitis E Serum, Human code: 95/584 (NIBSC, Англия). Иммунореагенты, полученные в ФГБНУ НИИВС им. И.И. Мечникова: рекомбинантный антиген ORF2/3-ВГЕ1/3, моноклональные антитела к IgG человека («Сорбент», Россия), конъюгированные с пероксидазой хрена, специфические поликлональные антитела кролика к белку ORF2/3-ВГЕ1/3, конъюгированные с IgG человека. Сыворотки крови здоровых людей и лиц, инфицированных вирусами гепатитов А, В, С, Е, ВИЧ и герпесвирусами. Результаты и обсуждение. Разработана иммуноферментная тест-система «Скрин-ВГЕ-IgG» для определения концентрации IgG к вирусу гепатита Е (МЕ/мл) в сыворотке крови человека в непрямом формате. Синтезирован и стандартизирован по международному ВОЗ-стандарту Anti-Hepatitis E Serum, Human, NIBSC code: 95/584, искусственный калибратор для определения концентрации АТ-ВГЕ. Определены основные функциональные характеристики «Скрин-ВГЕ-IgG» в соответст- вии с требованиями ГОСТ 51352-2013. Тест-система апробирована на образцах сывороток крови больных гепатитом Е (n = 75) и условно здоровых лиц (n = 320). По данным ROC-анализа, диагностическая чувствительность тест-системы составляет 98,7 %, диагностическая спе- цифичность — 99,9 %. Показано отсутствие перекрестной реактивности «Скрин-ВГЕ-IgG» на образцах с серологическими маркерами других вирусных гепатитов и патологии печени иной этиологии (n = 83). Сравнительные испытания тест-системы «Скрин-ВГЕ-IgG» и ее коммерческого аналога – набора реагентов recomWeel HEV IgG, — показали более высокую диагностическую чувствительность разработан- ной тест-системы. Заключение. Разработанная тест-система обладает высокими показателями диагностической эффективности и может быть рекомендована к применению в клинической практике для определения концентрации IgG-антител к ВГЕ. Introduction. To detect antibodies to the hepatitis E virus (HEV), the enzyme-linked immunosorbent assay (ELISA) is the preferred method with a quantitative assessment of results. This method, based on strict criteria, al- lows for the precise determination of the quantity of antibodies, enabling reliable diagnosis and epidemiological monitoring. The aim. To develop a test system for measuring the concentration of IgG antibodies against HEV in human serum using indirect ELISA, and to evaluate its diagnostic accuracy. Materials and methods. Reagents kits «DS-ELISA-ANTI-HEV-G» (Diagnostic Systems, Russia) and «recomWeel HEV IgG» (Euroimmun, Germany) were used, as well as WHO International Standard Samples of Anti- Hepatitis E Serum (NIBSC, England) and immunoreagents from the «I.I. Mechnikov Research Institute of Vaccines and Sera»: recombinant antigen ORF2/3-HEV1/3, monoclonal antibodies to human IgG conjugated with horseradish peroxidase (Sorbent, Russia), and specific polyclonal rabbit antibodies for the protein ORF2/3-HEVI/3 conjugated with human IgG. Blood serum samples from healthy individuals and those infected with hepatitis A, B, C, E, HIV and herpes viruses. Results and discussion. It has been developed of enzyme immunoassay kit reagents called «Screen-HEV-IgG» to determine the concentration of hepatitis E virus IgG (AT-HEV) in human blood serum. The kit uses an indirect ELISA method to measure the concentration of AT-HEV in IU/ml. An artificial calibrator has been synthesized and standardized based on the World Health Organization's...
- Open Access
- 28 December 2025
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 102 (6) , 693-701
Hepatitis A virus seroprevalence in Kyrgyzstan
Introduction. Kyrgyzstan, among other Central Asian countries, is one of the highly endemic regions for hepatitis A. An important tool for assessing the true burden of these infections on the population and the success of ongoing prevention programs is to study the prevalence of markers of past and current hepatitis A in all age groups of the population, as well as the intensity of population immunity to this virus in regions with different morbidity. Aim. To study the hepatitis A virus (HAV) seroprevalence among residents of the Kyrgyzstan regions. Materials and methods. Blood serum samples from conditionally healthy individuals (n = 2297) who sought medical attention at medical institutions in Bishkek, Batken, Chüy, Jalal-Abad, Issyk-Kul, Osh, Talas and Naryn regions. IgM and IgG antibodies to hepatitis A virus (anti-HAV IgM, anti-HAV IgG) were determined using the «Vectohep A-IgM» and «Vectohep A-IgG» (Vector-Best) enzyme immunoassay kits. Statistical processing of the results was carried out using Excel and Medcalc programs. Results. 80.3% of the studied samples contained HAV serologic markers, of which 80.3% contained anti-HAV IgG antibodies and 4.7% contained anti-HAV IgM antibodies. All IgM-positive samples contained specific IgG antibodies. Such samples were identified with the same frequency among women and men. The highest seropositivity rates were observed in the age groups 30–39, 40–49, and 50–59 years. The number of individuals with anti-HAV IgG antibodies in their blood serum increased with their age. An analysis of the immunostructure of the examined individuals by the level of anti-HAV IgG in serum showed relatively stable ratios of low, medium and high levels of antibodies in groups older than 30 years. The most frequently anti-HAV IgM and IgG antibodies were detected in samples from residents of Bishkek. Anti-HAV IgG antibodies were detected in samples from all surveyed regions of Kyrgyzstan, while anti-HAV IgM antibodies were identified in samples from Chüy, Issyk-Kul and Osh regions, as well as Bishkek. Conclusion. Hepatitis A remains widespread in Kyrgyzstan. The determination of HAV seromarkers in the algorithms of complex hepatitis diagnostics and seroepidemiological studies remains relevant. A decrease in the level of population immunity to HAV in younger age group indicates the country's transition from high to medium endemicity, which suggests an increase in the number of clinically pronounced cases in the future in the absence of a hepatitis A vaccination program for children.
- 28 December 2025
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 102 (6) , 693-701
Open AccessHepatitis A virus seroprevalence in Kyrgyzstan
Introduction. Kyrgyzstan, among other Central Asian countries, is one of the highly endemic regions for hepatitis A. An important tool for assessing the true burden of these infections on the population and the success of ongoing prevention programs is to study the prevalence of markers of past and current hepatitis A in all age groups of the population, as well as the intensity of population immunity to this virus in regions with different morbidity. Aim. To study the hepatitis A virus (HAV) seroprevalence among residents of the Kyrgyzstan regions. Materials and methods. Blood serum samples from conditionally healthy individuals (n = 2297) who sought medical attention at medical institutions in Bishkek, Batken, Chüy, Jalal-Abad, Issyk-Kul, Osh, Talas and Naryn regions. IgM and IgG antibodies to hepatitis A virus (anti-HAV IgM, anti-HAV IgG) were determined using the «Vectohep A-IgM» and «Vectohep A-IgG» (Vector-Best) enzyme immunoassay kits. Statistical processing of the results was carried out using Excel and Medcalc programs. Results. 80.3% of the studied samples contained HAV serologic markers, of which 80.3% contained anti-HAV IgG antibodies and 4.7% contained anti-HAV IgM antibodies. All IgM-positive samples contained specific IgG antibodies. Such samples were identified with the same frequency among women and men. The highest seropositivity rates were observed in the age groups 30–39, 40–49, and 50–59 years. The number of individuals with anti-HAV IgG antibodies in their blood serum increased with their age. An analysis of the immunostructure of the examined individuals by the level of anti-HAV IgG in serum showed relatively stable ratios of low, medium and high levels of antibodies in groups older than 30 years. The most frequently anti-HAV IgM and IgG antibodies were detected in samples from residents of Bishkek. Anti-HAV IgG antibodies were detected in samples from all surveyed regions of Kyrgyzstan, while anti-HAV IgM antibodies were identified in samples from Chüy, Issyk-Kul and Osh regions, as well as Bishkek. Conclusion. Hepatitis A remains widespread in Kyrgyzstan. The determination of HAV seromarkers in the algorithms of complex hepatitis diagnostics and seroepidemiological studies remains relevant. A decrease in the level of population immunity to HAV in younger age group indicates the country's transition from high to medium endemicity, which suggests an increase in the number of clinically pronounced cases in the future in the absence of a hepatitis A vaccination program for children.
- Open Access
- 28 July 2025
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 24 (3) , 53-62
Assessment of the Prevalence of Markers of Monoinfection with Hepatitis C Virus and Coinfection with Hepatitis C and B Viruses among the Personnel of Medical Institutions of an Endemic Region
Relevance. Parenteral viral hepatitis B (HBV) and C (HCV) affect not only millions of people, but also healthcare workers due to professional contacts, which lead to the progression of liver pathology and a reduction in medical activity. Numerous studies have shown that patients with double infection are at greater risk of developing progressive liver disease, cirrhosis, and hepatocellular carcinoma compared to monoinfected patients.Aim. To assess the characteristics of the spread of latent forms of hepatitis C monoinfection and hepatitis C and B coinfection among healthcare workers depending on age and medical specialty.Materials and methods. A serological and epidemiological observational descriptive prospective study was conducted based on the analysis of the results of a study of 1,643 workers who were considered healthy and did not have documented HBV, HCV, from 3 inpatient and outpatient medical organizations in an area with an active course of epidemic processes. Employees who were initially vaccinated against HBV were 1,597 (97.2 %) people and 46 (2.8 %) people who were not vaccinated. Subjects are included in the study after receiving written consent. Antibody levels were assessed based on the аnti–HВsAg study using commercial ELISA kits "VectoHBsAg - antibodies" (Russia); the presence of antibodies to the nuclear antigen of hepatitis B virus (anti- НВс) by the HepaBest anti-HBc-IgG ELISA method (Russia); the presence of total antibodies to HCV-core and -NS by the ELISA method «HCV-AT Confirmatory» (Russia). Statistical processing and analysis of the research results were carried out using Microsoft Excel 2010 and Prism9 software (GraphPad, USA.Results and discussion. For the period under review (2023-2024) In the structure of HCV cases, 5 % of the study sample (1,643) were young people (up to 44 years old), while elderly and middle-aged people (45-60 years old) were more susceptible to combined forms of HCV and HBV (1.7 %). In the structure of professional categories suffering from HCV, the main share belongs to the nursing staff - 45.1 % (pConclusion. The analysis makes it possible to identify organizations at the place of suspected infection, identify ways and factors of transmission, take measures to eliminate violations of the anti-epidemic regime, leading to increased risks of infection, and thereby ensure the biosafety of working conditions for healthcare workers.
- 28 July 2025
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 24 (3) , 53-62
Open AccessAssessment of the Prevalence of Markers of Monoinfection with Hepatitis C Virus and Coinfection with Hepatitis C and B Viruses among the Personnel of Medical Institutions of an Endemic Region
Relevance. Parenteral viral hepatitis B (HBV) and C (HCV) affect not only millions of people, but also healthcare workers due to professional contacts, which lead to the progression of liver pathology and a reduction in medical activity. Numerous studies have shown that patients with double infection are at greater risk of developing progressive liver disease, cirrhosis, and hepatocellular carcinoma compared to monoinfected patients.Aim. To assess the characteristics of the spread of latent forms of hepatitis C monoinfection and hepatitis C and B coinfection among healthcare workers depending on age and medical specialty.Materials and methods. A serological and epidemiological observational descriptive prospective study was conducted based on the analysis of the results of a study of 1,643 workers who were considered healthy and did not have documented HBV, HCV, from 3 inpatient and outpatient medical organizations in an area with an active course of epidemic processes. Employees who were initially vaccinated against HBV were 1,597 (97.2 %) people and 46 (2.8 %) people who were not vaccinated. Subjects are included in the study after receiving written consent. Antibody levels were assessed based on the аnti–HВsAg study using commercial ELISA kits "VectoHBsAg - antibodies" (Russia); the presence of antibodies to the nuclear antigen of hepatitis B virus (anti- НВс) by the HepaBest anti-HBc-IgG ELISA method (Russia); the presence of total antibodies to HCV-core and -NS by the ELISA method «HCV-AT Confirmatory» (Russia). Statistical processing and analysis of the research results were carried out using Microsoft Excel 2010 and Prism9 software (GraphPad, USA.Results and discussion. For the period under review (2023-2024) In the structure of HCV cases, 5 % of the study sample (1,643) were young people (up to 44 years old), while elderly and middle-aged people (45-60 years old) were more susceptible to combined forms of HCV and HBV (1.7 %). In the structure of professional categories suffering from HCV, the main share belongs to the nursing staff - 45.1 % (pConclusion. The analysis makes it possible to identify organizations at the place of suspected infection, identify ways and factors of transmission, take measures to eliminate violations of the anti-epidemic regime, leading to increased risks of infection, and thereby ensure the biosafety of working conditions for healthcare workers.
- Open Access
- 6 January 2022
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 20 (6) , 72-80-80
Development of the ELISA Test System for Quantitative Determination of IgG to the Varizella zoster virus in Human Serum and Assessment of its Diagnostic Efficiency
Relevance. The introduction of Varicella vaccine prophylaxis explains the need to develop a methodology for monitoring the vaccination effectiveness and the intensity of population immunity. This problem can be solved using quantitative immunoassay methods. Aim. Development of an enzyme-linked immunosorbent assay for the concentration of class G immunoglobulins (AB) to Varicella zoster virus (VZV) determining and assessing its functional characteristics and diagnostic efficiency. Materials and methods. Recombinant antigen GE VZV. WHO International Standard for Antibodies to VZV W1044. Blood serum samples from healthy people and patients with Chickenpox and Herpes zoster, blood serum samples containing IgG antibodies to herpes simplex viruses of the first and second types, cytomegalovirus, Epstein-Barr virus. Anti-VZV ELISA (IgG) reagent kit (Euroimmun, Germany). Indirect enzyme-linked immunosorbent assay. Immunization of animals with recombinant antigen GE, isolation, and purification of specific antibodies. Conjugation of monoclonal antibodies to human IgG with antibodies to antigen GE and with horseradish peroxidase. Results. An enzyme-linked immunosorbent assay in «an indirect» format has been developed to determine the specific antibodies to VZV concentration (IU/ml) in human serum/plasma. An artificial calibrator for determining the concentration of AB-VZV had been synthesized and standardized according to the International WHO-standard W1044. The main functional characteristics of the developed enzyme-linked immunosorbent assay are determined in accordance with GOST 51352-2013. The diagnostic kit was tested on blood serum samples from children with chickenpox (n = 43), adults with Herpes zoster (n = 158), healthy individuals (n = 781). The diagnostic sensitivity of the test system was 85%, the diagnostic specificity was 87% according to the ROC analysis. The absence of cross-reactivity of the test system was shown on samples with serological markers of other herpesvirus infections (n = 94). Comparative trials of the developed test system and its commercial analog, the Anti-VZV ELISA (IgG) reagent kit, did not reveal statistically significant differences between their functional characteristics. Conclusions. The developed test system for determining of the AB-VZV concentration in human serum/plasma in terms of its functional characteristics meets the GOST requirements, is characterized by high diagnostic efficiency, can be used to monitor the effectiveness of vaccine prophylaxis and strength of population immunity, as well as to assess the immune response in chickenpox and Herpes zoster.
- 6 January 2022
- Published by LLC Numicom in Epidemiology and Vaccinal Prevention
- Vol. 20 (6) , 72-80-80
Open AccessDevelopment of the ELISA Test System for Quantitative Determination of IgG to the Varizella zoster virus in Human Serum and Assessment of its Diagnostic Efficiency
Relevance. The introduction of Varicella vaccine prophylaxis explains the need to develop a methodology for monitoring the vaccination effectiveness and the intensity of population immunity. This problem can be solved using quantitative immunoassay methods. Aim. Development of an enzyme-linked immunosorbent assay for the concentration of class G immunoglobulins (AB) to Varicella zoster virus (VZV) determining and assessing its functional characteristics and diagnostic efficiency. Materials and methods. Recombinant antigen GE VZV. WHO International Standard for Antibodies to VZV W1044. Blood serum samples from healthy people and patients with Chickenpox and Herpes zoster, blood serum samples containing IgG antibodies to herpes simplex viruses of the first and second types, cytomegalovirus, Epstein-Barr virus. Anti-VZV ELISA (IgG) reagent kit (Euroimmun, Germany). Indirect enzyme-linked immunosorbent assay. Immunization of animals with recombinant antigen GE, isolation, and purification of specific antibodies. Conjugation of monoclonal antibodies to human IgG with antibodies to antigen GE and with horseradish peroxidase. Results. An enzyme-linked immunosorbent assay in «an indirect» format has been developed to determine the specific antibodies to VZV concentration (IU/ml) in human serum/plasma. An artificial calibrator for determining the concentration of AB-VZV had been synthesized and standardized according to the International WHO-standard W1044. The main functional characteristics of the developed enzyme-linked immunosorbent assay are determined in accordance with GOST 51352-2013. The diagnostic kit was tested on blood serum samples from children with chickenpox (n = 43), adults with Herpes zoster (n = 158), healthy individuals (n = 781). The diagnostic sensitivity of the test system was 85%, the diagnostic specificity was 87% according to the ROC analysis. The absence of cross-reactivity of the test system was shown on samples with serological markers of other herpesvirus infections (n = 94). Comparative trials of the developed test system and its commercial analog, the Anti-VZV ELISA (IgG) reagent kit, did not reveal statistically significant differences between their functional characteristics. Conclusions. The developed test system for determining of the AB-VZV concentration in human serum/plasma in terms of its functional characteristics meets the GOST requirements, is characterized by high diagnostic efficiency, can be used to monitor the effectiveness of vaccine prophylaxis and strength of population immunity, as well as to assess the immune response in chickenpox and Herpes zoster.
- Open Access
- 21 July 2020
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 65 (3) , 132-142-142
Line immunoassay for detection of IgG antibodies to hepatitis E virus (Hepeviridae, Orthohepevirus, Orthohepevirus A)
Introduction. The diagnostic efficacy of methods for hepatitis E serodiagnostic varies over a wide range; therefore, the combined use of tests of various formats is recommended. The aim of the research was to develop a test system for the detection of IgG antibodies to hepatitis E virus (HEV) in human serum by linear immunoassay (LIA). Material and methods. Serum samples from patients with hepatitis and healthy individuals were tested using commercial enzyme-linked immunosorbent assay systems for the presence of IgG antibodies to viral agents causing hepatitis and other infections associated with liver pathology. Recombinant antigens ORF2 and ORF3 of HEV genotypes 1 and 3 were used. The “RecomLine HEV IgG/IgM” reagent kit (Mikrogen GmbH, Germany) was used as a comparison test system. Results. The first Russian diagnostic kit “Blot-HEV”, designed to detect IgG antibodies to individual HEV proteins in human serum using LIA, was developed. The antigenic base is represented by strips of a nitrocellulose membrane with immobilized recombinant antigens ORF2 (aa 406–660) and ORF3 (aa 1–113) of HEV genotypes 1 and 3, and control antigens in the form of discrete lines. The conjugate was mouse monoclonal antibodies to human class G immunoglobulins labeled with horseradish peroxidase. The chromogen solution contained the 3,3’,5,5’-tetramethylbenzidine. A visual and digital recording of results was provided. The analytical sensitivity of the test kit was 0.625 IU/ml for ORF2 antigens and 2.5 IU/ml for ORF3 antigens. The absence of the influence of endogenous interfering substances on the results of the analysis and the absence of cross-reactions with antibodies to hepatitis pathogens of the other etiologies had been shown. The sensitivity of the test system compared to the “RecomLine HEV IgG/IgM” kit was 92%, specificity 97%. Shelf life in condition of storage was determined to be 12 months. Conclusions. The developed test can be used to confirm the results of ELISA in laboratory diagnosis of hepatitis E.
- 21 July 2020
- Published by Central Research Institute for Epidemiology in Problems of Virology
- Vol. 65 (3) , 132-142-142
Open AccessLine immunoassay for detection of IgG antibodies to hepatitis E virus (Hepeviridae, Orthohepevirus, Orthohepevirus A)
Introduction. The diagnostic efficacy of methods for hepatitis E serodiagnostic varies over a wide range; therefore, the combined use of tests of various formats is recommended. The aim of the research was to develop a test system for the detection of IgG antibodies to hepatitis E virus (HEV) in human serum by linear immunoassay (LIA). Material and methods. Serum samples from patients with hepatitis and healthy individuals were tested using commercial enzyme-linked immunosorbent assay systems for the presence of IgG antibodies to viral agents causing hepatitis and other infections associated with liver pathology. Recombinant antigens ORF2 and ORF3 of HEV genotypes 1 and 3 were used. The “RecomLine HEV IgG/IgM” reagent kit (Mikrogen GmbH, Germany) was used as a comparison test system. Results. The first Russian diagnostic kit “Blot-HEV”, designed to detect IgG antibodies to individual HEV proteins in human serum using LIA, was developed. The antigenic base is represented by strips of a nitrocellulose membrane with immobilized recombinant antigens ORF2 (aa 406–660) and ORF3 (aa 1–113) of HEV genotypes 1 and 3, and control antigens in the form of discrete lines. The conjugate was mouse monoclonal antibodies to human class G immunoglobulins labeled with horseradish peroxidase. The chromogen solution contained the 3,3’,5,5’-tetramethylbenzidine. A visual and digital recording of results was provided. The analytical sensitivity of the test kit was 0.625 IU/ml for ORF2 antigens and 2.5 IU/ml for ORF3 antigens. The absence of the influence of endogenous interfering substances on the results of the analysis and the absence of cross-reactions with antibodies to hepatitis pathogens of the other etiologies had been shown. The sensitivity of the test system compared to the “RecomLine HEV IgG/IgM” kit was 92%, specificity 97%. Shelf life in condition of storage was determined to be 12 months. Conclusions. The developed test can be used to confirm the results of ELISA in laboratory diagnosis of hepatitis E.